Glenmark Pharmaceuticals Gets CDSCO Panel Nod to Study Lobeglitazone Sulfate, Glimepiride FDC Table

New Delhi: Glenmark Pharmaceuticals, a major pharmaceutical company, has received approval from the Subject Expert Committee (SEC) operating under the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase IV clinical trials for the antidiabetic drug combination of Lobeglitazone Sulfate 0.5 mg and Glimepiride 1 mg tablet.

However, this approval is subject to the condition that the firm should defined the upper limit for HbA1c, specifically not more than 9%, under the inclusion criteria.

This came after Glenmark Pharmaceuticals presented their proposal for the grant of permission to conduct Phase IV clinical trials for the Lobeglitazone Sulfate 0.5 mg and Glimepiride 1 mg tablet.

Lobeglitazone is an antidiabetic medication belonging to the thiazolidinedione class, primarily functioning as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting insulin binding at fat cells, lobeglitazone has been shown to reduce blood sugar levels, lower HbA1c levels, and improve lipid and liver profiles.

Glimepiride is used to treat high blood sugar levels caused by type 2 diabetes, either alone or in combination with insulin or another oral medicine such as metformin. In type 2 diabetes, insulin produced by the pancreas is not able to transport sugar into the body’s cells where it can function effectively.

During the recent SEC meeting for Endocrinology and Metabolism held on March 21, 2024, the expert panel reviewed Glenmark’s proposal for permission to conduct Phase IV clinical trials for the Lobeglitazone Sulfate 0.5 mg and Glimepiride 1 mg tablet.

Following extensive deliberation, the committee recommended conducting Phase IV clinical trials with drug FDC of Lobeglitazone Sulfate 0.5 mg and Glimepiride 1 mg tablet as per the presented protocol, with the condition that the firm should defined the upper limit for HbA1c, specifically not more than 9%, under the inclusion criteria.

Also Read:Submit analysis of clinical data of Asian, Indian Population: CDSCO Panel Tells AstraZeneca on Durvalumab

Powered by WPeMatico

FedEx Courier Scam: Delhi Doctor loses Rs 5 lakh to fraudsters

New Delhi: In yet another incident of the FedEx courier scam, a woman doctor in Delhi was duped of Rs 5 lakh by fraudsters who posed as FedEx personnel and Mumbai Police cyber crime officers. 

According to the police, the doctor lost the money in a fake drug parcel scam orchestrated by the fraudsters who coerced and manipulated her into transferring the amount to their account. 

Although the police have registered an FIR against the unidentified fraudsters under Section 420 in the Indian Penal Code (IPC) which deals with Cheating and dishonestly inducing delivery of property, no arrests have been made so far. 

Also read- Pune Doctor Duped By Fraudsters In Drug Parcel Scam, Loses Rs 1 Crore

In her complaint, the 35-year-old doctor, a resident of south Delhi’s Chhatarpur said that she was forced to transfer the money as the fraudsters observed her every move in a three-hour video call on Skype.   

The incident occurred on April 6 when the doctor received a call about a seizure of a parcel from abroad. The suspect informed her that the customs officials at Mumbai airport seized a parcel in her name that contained five illegal passports, three credit cards, 5 kg of clothes and 200 gm of MDMA drugs.

After she refused the claims of the suspect, she was connected to another call with another suspect posed as an inspector in the Mumbai cyber cell who claimed that they had details of her documents along with multiple bank accounts under her name.

“I was connected to a man who posed as an inspector in the Mumbai cyber cell. The officer had my Aadhaar card number and said my name was being used to create multiple bank accounts in Mumbai, Goa, and Bengaluru. He said that there are three money laundering and a drugs case registered against my name,” she told HT.

“The man on the call said he was DCP Bal Singh Thakur from Mumbai Police. He said that a criminal who’s involved in drugs and money laundering cases had accessed my details and made all those accounts. He sent me two official letters saying that I would have to empty 98% of my bank balance as police need to check the money and its source,” she added.

Consequently, the doctor sat for three hours with the suspects on a video call under the pretext of verification. After the officer said that she had no other option but to provide the money, the doctor agreed and followed the instructions accordingly. 

Being unable to disconnect or pause the video call, the doctor was forced to transfer Rs 5.10 lakhs to a bank account in Mumbai. However, she was promised that she would receive the money back in 15 minutes, but never received it. 

Realising that she fell victim to cyber criminals, she approached the police and filed a complaint on the same day. 

“They threatened that they have my address and (can) pick (me) up from (my) house and that I am named in a money laundering case and narcotics case. He said what happened with Shah Rukh Khan’s son Aryan Khan can happen to me too or worse…” she said in her complaint. 

The doctor in Delhi has become the most recent target of the “FedEx scam,” as reported by the Delhi Police. It is believed that the doctor was victimized by the same scammers who previously targeted a lawyer in Bengaluru last week, causing her to lose over ₹15 lakh and coercing her to strip during a video call for a fake narcotics test.

Also read- Hyderabad: Man Poses As Doctor On Matrimonial Website Dupes Woman Of Rs 6 Lakh

Powered by WPeMatico

5 resident doctors of Gandhi Medical College, Hamidiya Hospital, Bhopal threaten mass suicide

Alleging toxic work culture, 5 resident doctors of Gandhi Medical College, Hamidiya Hospital, Bhopal, have threatened to commit mass suicide on 31st May 2024 if the authorities do not address their complaints. The doctors have demanded the authorities to stop the non-stop working hours which can go for more than 24 hours and sometimes 36 hours. They have further urged the authorities to ensure a healthy working environment and to stop the toxicity and abuse.

Writing to the Federation of All India Medical Association (FAIMA), the doctors said “If proper and immediate steps will not be taken within two months.. Then to lodge our protest we 5 residents will do suicide in a single day on 31st May 2024. This College and hospital will be famous for suicide and toxicity in the future. This letter could also be considered as our suicide note.”

For more details, check out the full story on the link below:

Toxic Work Culture Allegations Rocks Gandhi Medical College Bhopal: 5 Resident Doctors Threaten Mass Suicide

Powered by WPeMatico

Health Bulletin 16/ April/ 2024

Here are the top health stories for the day:

Gandhi Medical College Bhopal: 5 Resident doctors threaten mass suicide due to toxic culture

Alleging toxic work culture, 5 resident doctors of Gandhi Medical College, Hamidiya Hospital, Bhopal, have threatened to commit mass suicide on 31st May 2024 if the authorities do not address their complaints. The doctors have demanded the authorities to stop the non-stop working hours which can go for more than 24 hours and sometimes 36 hours. They have further urged the authorities to ensure a healthy working environment and to stop the toxicity and abuse.

Writing to the Federation of All India Medical Association (FAIMA), the doctors said “If proper and immediate steps will not be taken within two months.. Then to lodge our protest we 5 residents will do suicide in a single day on 31st May 2024. This College and hospital will be famous for suicide and toxicity in the future. This letter could also be considered as our suicide note.”

For more details, check out the full story on the link below:

Toxic Work Culture Allegations Rocks Gandhi Medical College Bhopal: 5 Resident Doctors Threaten Mass Suicide

Retired ENT surgeon duped of ₹5.37cr in lure of ‘space in heaven’

A retired ENT surgeon from Kondhwa, aged 67, fell victim to an alleged scam amounting to ₹5.37 crore, orchestrated under the guise of religious services promising spiritual rewards, including a 'space in heaven.' The incident unfolded between October 2018 and April 2024, with suspects identified as Sadiq Sheikh,

Yasmin Sheikh, Etesham Sheikh, Aman Sheikh, and Raj Narsu. Police officials revealed that the suspects exploited the doctor's trust, initiall engaging him in religious discussions before manipulating him into transferring property documents and surrendering assets. They allegedly coerced him into procuring 11 reward certificates for various properties and relinquishing cash, gold articles, and gold biscuits.


India rubbishes Lancet report, says spending on healthcare is at all-time high

Following a Lancet report on low healthcare spending, government sources defended their efforts, stating allocation is at an all-time high. The National Health Policy aims for 2.5% of GDP by 2025, urging states to boost health budgets annually. Budget estimates for Health and Family Welfare surged from Rs 36,948 crore in 2014-15 to Rs 86,175 crore in 2023-24, a 133.23% increase.

The 15th Finance Commission allocated Rs 70,051 crore for health grants through local governments. National Health Accounts show a rise in total health expenditure from Rs 4,83,259 crore in 2014-15 to Rs 6,55,822 crore in 2019-20. Government health spending as a percent of GDP increased from 1.13% to 1.35%, with out-of-pocket expenditure decreasing from 62.6% to 47.1%.

Powered by WPeMatico

Max Healthcare to double bed capacity in 4-5 years, will invest Rs 2500 cr in UP

New Delhi: Max Healthcare Institute Ltd has announced expansion plans, intending to invest over Rs 5,000 crore to significantly increase its bed capacity to over 8,000 beds within the next four to five years.

The Chairman and Managing Director, Abhay Soi, disclosed that half of this investment will be allocated to Uttar Pradesh (UP), emphasizing the state’s growing economic prospects

Following the acquisition of Sahara Hospital in Lucknow last year, it has been renamed Max Super Specialty Hospital, Lucknow.

According to a PTI report, It plans to invest Rs 2,500 crore in Uttar Pradesh (UP) which includes setting up of a new 500 beds hospital on 5.6-acre parcel of land located at Shaheed Path and augmentation of capacity of the acquired facility.  

The healthcare major expects to create over 10,000 jobs through its two facilities in the state.

Also Read:Max Healthcare acquires 200-bed Alexis Hospital, Nagpur for Rs 412 crores

“UP is a state which is marching towards becoming a USD 1 trillion economy by 2027. There is a tremendous amount of development which is happening.

“For the development of any economy it is a prerequisite that healthcare also develops over there… We wanted to participate in the development of the state,” Soi told PTI.

He further said, “Given the development which is happening (in the state) and the increase in per capita income, it calls for much larger investment in healthcare.”

On the immediate expansion in UP, he said at Max Super Specialty Hospital, Lucknow, which is a 550-bed hospital, the company is “looking at expanding by another 300-odd beds going forward”.

“Other than this we have acquired land for a greenfield hospital at Shaheed Path for another 500 beds. Between these, we will have over 2,000 beds in the next few years… This would be at an investment of Rs 2,500 crore and we will be employing more than 10,000 people.”

With this, Max Healthcare will be the largest private healthcare network in UP, he asserted.

When asked if Max Healthcare Institute will be focussing only on UP for its expansion in the near future, he replied in the negative.

“We would look at other states too for expansion… We will be in multiple places as well,” Soi said, citing examples of how the company has expanded in Nagpur and Pune, and is also looking at other parts of the country.

On investments on overall expansion across India, he said it will be over Rs 5,000 crore in the next four to five years to more than double the bed capacity to over 8,000 beds.

At present, the company has 4,000 operational beds and is looking to add another 4,200 beds in the next four to five years.

When asked if the company would go for acquisitions only or set up new facilities for the planned expansions, Soi said, “It will be both. Where we can do acquisitions we would like to do acquisitions… we have seen in Lucknow itself, we have done one acquisition and the other is a greenfield.

If we get another, we’d be happy to do it.” On the funding of the expansion in UP, he said it will be through internal accruals.

“We are a debt-free company and we generate enough internal accruals to fund it,” Soi said.

Max Healthcare said it will introduce state-of-the-art cancer care and robotic surgical systems besides strengthening the organ transplantation program at Max Super Speciality Hospital, Lucknow.

It will bring in high-end tertiary and quaternary care to patients in Lucknow and neighbouring areas and the hospital will serve as an important referral centre for patients from Eastern and Central Uttar Pradesh and Bihar.

“With direct flight connectivity to several countries, the company will also explore attracting medical value travel patients from neighbouring countries and the Middle East to Max Super Speciality Hospital, Lucknow,” the company added.

Powered by WPeMatico

Cipla Health to acquire Ivia Beaute’s cosmetics, personal care distribution and marketing business for Rs 130 crore

Mumbai: Cipla Limited has announced that Cipla Health Limited, the
wholly owned subsidiary and consumer healthcare arm of the Company, has signed a
business transfer agreement (“BTA”) for purchase of the distribution and marketing
business undertaking of cosmetics and personal care business (“Undertaking”) of Ivia
Beaute Private Limited, India (“IVIA”) including IVIA’s brands namely Astaberry, Ikin and Bhimsaini on a worldwide basis.

On the cost of acquisition, Cipla said it will be “Rs 130 crore on the closing date and Rs 110 crore contingent upon achievement of certain financial parameters (milestones) for next 3 years as mentioned in the BTA”.

“This strategic move is aligned with Cipla’s focus on
enhancing its consumer healthcare and wellness portfolio.
Building on its strong presence through a cluster of brands in Tier 2-6 towns, CHL is
strengthening its play in the fast-growing beauty and personal care sector catering to
the aspirational consumer of India. The growing adoption of beauty and personal care
products in Indian households signals a prominent trend, positioning the market as crucial
for CHL’s expansion efforts,” the release stated.

With a brand legacy of over 16 years, Astaberry caters to
consumers through a wide range of unique products to help them address their skincare
needs. These brands complement CHL’s offerings in the skin care segment and enriches
the portfolio with solutions for consumers.

The transfer of “Undertaking” is subject to completion of certain conditions mentioned in
the BTA. Pursuant to completion of such conditions, CHL shall initiate the distribution and
marketing of the products.

Commenting on the development, Shivam Puri, Chief Executive Officer and Whole Time
Director of CHL said, “This move not only solidifies our presence in the expansive and
dynamic beauty and personal care sector but also builds on our well-established
footprint in Tier 2-6 cities. Our target consumer base is discerning and seeks variety,
especially when it comes to new brands in personal care. Integrating Astaberry, Ikin and Bhimsaini into our portfolio seamlessly complements our existing offerings across key
OTC/consumer healthcare categories, empowering us to deliver comprehensive
solutions that cater effectively to the diverse everyday needs of our consumers.”

CHL, through this acquisition, is well positioned to tap the beauty and personal care
category owing to its strong offline and online distribution muscle and a consumer insights
engine that has already helped create over 20 strong brands within the portfolio across
all key categories: Smoking Cessation (Nicotex), Cough and Cold Therapies (Cofsils and
Naselin), Pain Care (Omnigel), Analgesic (Paracip), Oral Rehydration Therapy/
Beverages (Prolyte), Vitamins, Minerals and Supplements (Maxirich), Topical Antiseptics
(Cipladine), Anti-fungal solutions (Clocip), Weight Gain (Endura Mass), Mother, Child and
Feminine Hygiene (Mamaxpert and Evexpert) and Skin and Hair Care (Cetafresh, Rivela
and Tugain). Most of these brands have attained leadership positions in their respective
categories.

Read also: Cipla Gets CDSCO Panel Nod To import, market Human Insulin inhalation powder with inhaler

Powered by WPeMatico

INI SS July 2024: 3 seats added to DM Nephrology at AIIMS Delhi, details

New Delhi- The examination section of All India Institute of Medical Sciences (AIIMS) has informed about the addition of 3 more seats for the DM Nephrology candidates appearing in the Institute of National Importance Super-Specialty Entrance Examination (INI-SS) for admission to DM, MCH and MD (Hospital Administration) courses for July 2024 session.

As per the notice, 3 seats have been added to the general category for the DM Nephrology specialization. Earlier, there were 2 in General, and 5 in sponsored, now as per the revised seat matrix, general and sponsored both categories have 5 seats each.

SEAT MATRIX

S.NO

SUBJECT

INSTITUTE

EARLIER SEATS

REVISED SEATS

1

DM- Nephrology

AIIMS New Delhi

General

SPONSORED

Foreign National

General

SPONSORED

Foreign National

2

5

0

5

5

0

INI-SS for July 2024 session is planned to be held in 16 cities in India such as Ahmedabad, Puducherry, Bhopal, Bhopal. It is been conducted for the admission to DM, MCh and MD (Hospital Administration) courses in AIIMS, PGIMER, NIMHANS, SCTIMST and JIPMER for the July 2024 session.

However, the registration process for the said course has been closed at 5:00 PM on Wednesday, 10th April 2024.

Meanwhile, other processes of INI-SS for admission to DM, MCh and MD (Hospital Administration) courses for the July 2024 session are currently ongoing.

Last date for submission of required documents for Regularisation of Rejected Applications. No Correspondence will be entertained after the given date under any circumstances and candidates are requested NOT TO CONTACT the Examination Section.

16.04.2024

Tuesday

Last date for Ministry of Health & Family Welfare, Govt. of India to forward an approval regarding “No Objection” to the Foreign National. Sponsorship certificates duly signed by competent authority for candidates applying under Sponsored seats should also be reached at the Examination Section.

16.04.2024

Tuesday

Submission of Certificate for Scribe and/or Compensatory time as applicable (Performa A-1/A-2/ A-3 of Appendix A)

17.04.2024

21.04.2024

Finalization of Centers and allotment of Roll No’s/Admit Cards on the website

22.04.2024

Monday

Written Test through online (CBT) mode

27.04.2024

Saturday

Last date for fulfilment of Eligibility for admission

31.07.2024

Last date for admission to the course

31.08.2024

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/addendum-delhi-236257.pdf

Powered by WPeMatico

Can animals count? Neuroscientists identify a sense of numeracy among rodents

A discovery that appears to confirm the existence of discrete number sense in rats has been announced by a joint research team from City University of Hong Kong (CityUHK) and The Chinese University of Hong Kong (CUHK).

Powered by WPeMatico

Pressure to lose weight in adolescence linked to how people value themselves almost two decades later

People who as teenagers felt pressure to lose weight from family or from the media, females, people who are not heterosexual, and people experiencing socioeconomic disadvantage, are most at risk of ‘internalized’ weight stigma, new research led by the University of Bristol has found. The study is published in The Lancet Regional Health – Europe.

Powered by WPeMatico

Many people with breast cancer ‘systematically left behind’ due to inaction on inequities and hidden suffering

Breast cancer is now the world’s most common cancer; at the end of 2020, 7.8 million women were alive after having been diagnosed in the previous five years. In the same year, 685,000 women died from the disease. Despite significant improvements in research, treatment, and survival, gross inequities persist, and many patients are being systematically left behind. This is a global blunder, says a new Lancet Commission.

Powered by WPeMatico